Compare CXDO & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXDO | VYGR |
|---|---|---|
| Founded | 1995 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.1M | 203.6M |
| IPO Year | 1999 | 2015 |
| Metric | CXDO | VYGR |
|---|---|---|
| Price | $6.91 | $3.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $9.20 | ★ $16.50 |
| AVG Volume (30 Days) | 457.0K | ★ 737.1K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 166.67 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $68,167,000.00 | $10,135,000.00 |
| Revenue This Year | $45.26 | $34.04 |
| Revenue Next Year | $13.31 | $7.92 |
| P/E Ratio | $340.50 | ★ N/A |
| Revenue Growth | ★ 12.05 | N/A |
| 52 Week Low | $5.26 | $2.88 |
| 52 Week High | $11.23 | $5.55 |
| Indicator | CXDO | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 40.88 | 38.00 |
| Support Level | $6.54 | $2.96 |
| Resistance Level | $7.02 | $4.33 |
| Average True Range (ATR) | 0.44 | 0.17 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 40.46 | 13.16 |
Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services. The company operates through two segments: Cloud telecommunications and Software Solutions. Its cloud telecommunications segment offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over any high-speed Internet connection. The Software Solutions segment is involved in revenue generation from software licenses, software maintenance support, and professional services. It generates subscription and maintenance support revenue from customer support and other supportive services. The company offers warranties on its products. It derives a majority of its revenue from the Cloud telecommunications segment.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.